BIXT 8-K
Bioxytran, Inc (BIXT)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact Name if Business Issuer as specified in its Charter)
| (State or other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification Number) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 1 4a- 12 under the Exchange Act (17 CFR 240.1 4a- 12) |
| Pre-commencement communications pursuant to Rule 1 4d-2(b) under the Exchange Act (17 CFR 240.1 4d-2(b)) |
| Pre-commencement communications pursuant to Rule 1 3e-4(c) under the Exchange Act (17 CFR 240.1 3e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| |
OTC Pink |
Item 8.01 Other Events.
On May 12th, 2022, the International Bureau of the Patent Cooperation Treaty (PCT) approved and published two patent applications from Bioxytran, Inc.:
| ● | WO 2022/099061 - Polysaccharides for Use in Treating Sars-Cov-2 Infections - The invention provides a method for treating SARS-CoV-2 by administering an effective amount of galactomannans to a subject in need thereof. |
| ● | WO2022/099061 - Polysaccharides for IV Administration that Treat Sars-Cov-2 Infections - The invention provides a method for treating SARS-CoV-2 by administering an effective amount of pectin polysaccharides to a subject in need thereof. |
On June 8, 2022 United States Patent and Trademark Office (USPTO) approved the Trademark ProLectin to be published in the published in the Trademark Official Gazette (TMOG) on June 28, 2022.
1
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
2
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| By: | /s/ David Platt | |
| Name: | Dr. David Platt | |
| Title: | President and Chief Executive Officer | |
Dated: June 10, 2022 | ||
3
Exhibit 10.69
PATENT COOPERATION TREATY WO 2022/099052 PCT/US2021/058310 From the INTERNATIONAL BUREAU PCT To: NOTIFICATION CONCERNING AVAILABILITY OF THE PUBLICATION OF THE INTERNATIONAL APPLICATION MCDONALD, J. Cooper Clark & Elbing LLP 101 Federal Street 15th Floor Boston, MA 02110 ETATS-UNIS D’AMERIQUE Date of mailing (day/month/year) 12 May 2022 (12.05.2022) Applicant’s or agent’s file reference 51577-002WO2 IMPORTANT NOTICE International application No. PCT/US2021/058310 International filing date (day/month/year) 05 November 2021 (05.11.2021) Priority date (day/month/year) 06 November 2020 (06.11.2020) Applicant BIOXYTRAN, INC. The applicant is hereby notified that the International Bureau: ☒ has published the above-indicated international application on 12 May 2022 (12.05.2022) under No. WO 2022/099052 □ has republished the above-indicated international application on under No. WO For an explanation as to the reason for this republication of the international application, reference is made to INID codes (15), (48) or (88) (as the case may be) on the front page of the published international application. - A copy of the international application is available for viewing and downloading on WIPO’s website at the following address: https://patentscope.wipo.int/ (in the appropriate field of the structured search, enter the PCT or WO number). - The applicant may also obtain a paper copy of the published international application from the International Bureau by sending an e-mail to [email protected] or by submitting a written request to the contact details provided below. Warning: Following publication of the international application, applicants, agents and inventors may receive misleading requests for payment of fees that appear to come from the International Bureau of WIPO or other patent Offices which are unrelated to the processing of international applications under the PCT. Agents are particularly encouraged to be vigilant and alert their clients about this practice. Examples of such requests for payment which have been received by the International Bureau can be found at: http://www.wipo.int/pct/en/waming/pct_warning.htm. Please forward copies of any such requests to [email protected]. The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Authorized officer Xin Wang e-mail [email protected] Telephone No. +41 22 338 74 02 FormPCT/IB/311 (revised January 2020) |
Exhibit 10.70
WO 2022/099061 PCT/US2021/058321 PATENT COOPERATION TREATY From the INTERNATIONAL BUREAU PCT NOTIFICATION CONCERNING AVAILABILITY OF THE PUBLICATION OF THE INTERNATIONAL APPLICATION To: MCDONALD, J., Cooper Clark & Elbing LLP 101 Federal Street 15th Floor Boston, MA 02110 ETATS-UNIS D’AMERIQUE Date of mailing (day/month/year) 12 May 2022 (12.05.2022) Applicant’s or agent’s file reference 51577-003W02 IMPORTANT NOTICE International application No. PCT/US2021/058321 International filing date (day/month/year) 05 November 2021 (05.11.2021) Priority date (day/month/year) 06 November 2020 (06.11.2020) Applicant BIOXYTRAN, INC. The applicant is hereby notified that the International Bureau: has published the above-indicated international application on 12 May 2022 (12.05.2022) under No. WO 2022/099061 □ has republished the above-indicated international application on under No. WO For an explanation as to the reason for this republication of the international application, reference is made to INID codes (15), (48) or (88) (as the case may be) on the front page of the published international application. - A copy of the international application is available for viewing and downloading on WIPO’s website at the following address: https://patentscope.wipo.int/ (in the appropriate field of the structured search, enter the PCT or WO number). - The applicant may also obtain a paper copy of the published international application from the International Bureau by sending an e-mail to [email protected] or by submitting a written request to the contact details provided below. Warning: Following publication of the international application, applicants, agents and inventors may receive misleading requests for payment of fees that appear to come from the International Bureau of WIPO or other patent Offices which are unrelated to the processing of international applications under the PCT. Agents are particularly encouraged to be vigilant and alert their clients about this practice. Examples of such requests for payment which have been received by the International Bureau can be found at: http://www.wipo.int/pct/en/waming/pct_warning.htm. Please forward copies of any such requests to [email protected]. The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Authorized officer Xiaofan Tang e-mail [email protected] Telephone No. +41 22 338 74 02 Form PCT/IB/311 (revised January 2020)
Exhibit 10.71
 |
UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) |
Commissioner for Trademarks
www.uspto.gov
OFFICIAL USPTO NOTICE OF PUBLICATION UNDER 12(a)
U.S. Application Serial No. 90888912
Mark: PROLECTIN
International Class(es): 005
Owner: Pharmalectin, Inc.
Docket/Reference No. 51577-T02001
Issue Date: June 8, 2022
Your mark is scheduled to publish in the Trademark Official Gazette (TMOG) on June 28, 2022.
Your mark appears to be entitled to register on the Principal Register upon the acceptance of a statement of use, subject to any claims of concurrent use.
What happens when your mark publishes. Within 30 days of the publication date, any party who believes it will be damaged by the registration of the mark may file a notice of opposition (or extension of time) with the Trademark Trial and Appeal Board. If no objection is filed, we will issue a Notice of allowance.
View your mark in the TMOG after the publication date at https://tmog.uspto.gov/ by selecting your publication date in the “issues” field, entering your serial number in the “search by” field, and clicking on the magnifying glass.
Ensure that the information in the TMOG is correct. If any information is incorrect, promptly request correction using the “Post-Approval/Publication/Post-Notice of Allowance (NOA) Amendment” form at https://teas.uspto.gov/office/ppa/. For more information, see https://www.uspto.gov/trademark/trademark-updates-andannouncements/procedures-submitting-amendmentscorrections-trademark.
Direct questions about this notice to the Trademark Assistance Center (TAC)at 1-800-786-9199 (select option 1) or [email protected].
Email Address(es):